Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
An early study shows that half of patients with advanced melanoma who received a combination of ipilimumab (Yervoy) and nivolumab, an investigational medication, were alive almost three and a half years later (40 months). That is nearly double the amount of time reported in earlier studies that used either drug by itself.
According to the results of a large phase I study, a new drug called MK-3475 may benefit people with melanoma that has spread to other parts of the body. MK-3475 blocks the function of a protein called PD-1 (programmed death-1) found on T-cells, a type of white blood cell that directly helps fight disease. Because PD-1 keeps the immune system from destroying cancer cells, stopping PD-1 from working allows the immune system to better eliminate melanoma.
Results from a large clinical study show that treatment with ipilimumab (Yervoy) decreases the risk of melanoma coming back after surgery by roughly 25% for people diagnosed with high-risk stage III disease. However, this treatment causes serious side effects.
Results from a large study show that the combination of lapatinib (Tykerb) and trastuzumab (Herceptin) plus chemotherapy after surgery is not more effective than only trastuzumab plus chemotherapy for women with early-stage, human epidermal receptor 2 (HER2)-positive breast cancer.
In a large, ongoing study, results indicate that two common treatment regimens approved by the U.S. Food and Drug Administration are equally effective for metastatic colorectal cancer. Metastatic colorectal cancer is cancer that has spread to other parts of the body.
Results from a new study led by the National Cancer Institute suggest that adding chemotherapy with the drug docetaxel (Docefrez, Taxotere) to standard hormone therapy lengthens the lives of men newly diagnosed with metastatic hormone-sensitive prostate cancer.
In an analysis of two ongoing studies, researchers found that exemestane (Aromasin) was more effective at preventing hormone-sensitive breast cancer from returning for premenopausal women than tamoxifen (Nolvadex, Soltamox) when each drug was paired with ovarian function suppression.
In a recent study, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone.
Results from a recent study show that the drug lenvatinib could become a new, effective treatment option for patients with differentiated thyroid cancer that is resistant to standard radioiodine (RAI) therapy.
Early results from an ongoing study show that ibrutinib (Imbruvica) keeps relapsed chronic lymphocytic leukemia (CLL) from worsening for longer than ofatumumab (Arzerra), a standard treatment option for relapsed or refractory CLL.